DRd Superior to Rd Regardless of Time Since Last Therapy in Myeloma

SAN DIEGO – Daratumumab plus lenalidomide and dexamethasone (DRd) is superior to lenalidomide plus dexamethasone (Rd) regardless of time since last therapy, refractoriness to last line of therapy, or cytogenetic risk in relapsed/refractory multiple myeloma, according to an updated analysis of the pivotal POLLUX study presented at the American Society of Hematology (ASH) 58^th Annual Meeting and Exposition.¹

Daratumumab is a human monoclonal antibody targeting CD38 that demonstrated superior efficacy with lenalidomide and dexamethasone to Rd alone in a pre-specified interim analysis of the phase 3 POLLUX trial on relapsed/refractory multiple myeloma.

After a median follow-up of 17.3 months, updated results showed that responses continue to deepen in patients treated with DRd compared with those who received Rd.

With longer follow-up researchers found that treatment with DRd is associated with a 63% reduction in the risk of progression or death vs Rd alone (hazard ratio, 0.37; 95% CI, 0.28-0.50; P < .0001). Investigators observed similar findings across all analyses in the 1 to 3 prior treatment lines population.

The study showed that DRd is superior to Rd irrespective of time since last therapy and that DRd benefits patients refractory to last line of therapy. The daratumumab combination also improves outcomes regardless of cytogenetics risk.

Overall survival data are not yet mature. Researchers observed no new safety signals with longer follow-up.

Reference

1. Usmani SZ, Dimopoulos M, Belch A, et al. Efficacy of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients with 1 to 3 prior lines of therapy: Updated analysis of POLLUX. Paper presented at: American Society of Hematology (ASH) 58^th Annual Meeting and Exposition; December 3-6, 2016; San Diego, CA.